948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC

Схожие документы

• 595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab
  по: Enriqueta Felip, и др.
  Опубликовано: (2023-11-01)
• 790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)
  по: Enriqueta Felip, и др.
  Опубликовано: (2020-11-01)
• 948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC
  по: Christian Mueller, и др.
  Опубликовано: (2021-11-01)
• Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study
  по: Matthew G. Krebs, MD, и др.
  Опубликовано: (2024-11-01)
• First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
  по: Gligorov Joseph, и др.
  Опубликовано: (2010-07-01)